News | December 17, 2024
Merck to acquire HUB Organoids to advance cell culture portfolio
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
According to IQVIATM sales data for the 12-month period ending October 2024, the Vimpat Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million
SPARC to receive 55% equity in Tiller Therapeutics
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
Harnessing advanced data analysis for early detection, prevention and better outcomes
Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines
IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy
First and only PARP inhibitor to improve overall survival in early breast cancer
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
Subscribe To Our Newsletter & Stay Updated
